HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC, Supplement Ad Spending Points To Bigger Jump For Full Year

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement ad spending grew 23.5% in the 2013 first quarter after increasing 17% in 2012, Kantar Media data show. The OTC sector’s ad spend was not as large, but still strong, up 10% for first quarter 2013 after increasing 8% in full-year 2012.

You may also be interested in...



P&G Beauty’s Sluggish 2012: The Cost Of Cutting Back?

Kline’s Nancy Mills offers perspective on P&G performance in 2012 when the company saw its market share slip in certain personal-care categories. In her blog post, Mills attributes the erosion in part to the firm’s ongoing $10 billion cost-cutting initiative, which slowed new product introductions and left some brands under-supported in a highly competitive landscape, she says.

P&G Targets $10 Billion In Cost Savings In Four Years

P&G will $10 billion in costs by the end of fiscal 2016, firm says at Analyst Group of New York Conference Feb. 23. Firm aims to derive $3 billion of that from reduced overhead, with plans to cut 5,700 jobs by the end of next fiscal year.

Mobile Devices Reshape Advertising, But Pose Hurdles

Mobile device use is increasing faster than Internet use grew in the 1990s, yet most firms are failing to capitalize on this fertile marketing ground, according to a Google executive.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel